Division of Hematology, Department of Medicine, University of Washington, Seattle, WA.
Blood. 2023 Mar 9;141(10):1136-1146. doi: 10.1182/blood.2022015954.
Acute graft-versus-host disease (GVHD) is a rare complication after solid organ transplantation (SOT) that carries high mortality. Caused by immunocompetent donor leukocytes within the transplanted organ, which become activated against recipient tissues, GVHD typically develops 2 to 12 weeks after SOT and can affect the skin, gastrointestinal tract, liver, and bone marrow. Signs and symptoms are nonspecific and include a rash, nausea, appetite loss, diarrhea, and cytopenias. Pancytopenia from marrow-directed GVHD is the primary driver of mortality. The diagnosis of GVHD is often delayed but should be confirmed by biopsy of an affected organ. Evidence of donor chimerism in blood or marrow supports the diagnosis. When GVHD is diagnosed we initiate treatment with systemic corticosteroids. At that time, if GVHD only involves skin or oral mucosa we also decrease maintenance immunosuppression levels to allow the recipient to reject the donor immune cells. For GVHD involving the marrow we initiate an allogeneic hematopoietic cell donor search early. In this article, we describe 3 cases of GVHD after SOT, outline our approach to diagnosis and management, and then provide analysis of the 3 instructive cases.
急性移植物抗宿主病(GVHD)是实体器官移植(SOT)后的一种罕见并发症,死亡率很高。它是由移植器官内具有免疫能力的供体细胞激活针对受者组织引起的,通常在 SOT 后 2 至 12 周发生,可影响皮肤、胃肠道、肝脏和骨髓。其症状和体征无特异性,包括皮疹、恶心、食欲减退、腹泻和血细胞减少症。骨髓定向 GVHD 导致的全血细胞减少是导致死亡的主要原因。GVHD 的诊断通常会被延误,但应通过受影响器官的活检来确认。血液或骨髓中供者嵌合体的证据支持该诊断。一旦诊断为 GVHD,我们会开始使用全身性皮质类固醇进行治疗。此时,如果 GVHD 仅涉及皮肤或口腔黏膜,我们也会降低维持性免疫抑制水平,以使受者排斥供者免疫细胞。对于涉及骨髓的 GVHD,我们会尽早开始寻找同种异体造血细胞供体。在本文中,我们描述了 3 例 SOT 后的 GVHD 病例,概述了我们的诊断和管理方法,然后对这 3 个有启发性的病例进行了分析。